Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05027698
Other study ID # T138E4
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 27, 2021
Est. completion date August 3, 2022

Study information

Verified date September 2022
Source Terumo Europe N.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to further demonstrate the safety and effectiveness of the FemoSeal™ VCS in achieving hemostasis following percutaneous endovascular procedures performed via the common femoral artery (CFA) access site. This study is conducted in real-world subjects according to the FemoSeal™ VCS instruction for use (IFU), as part of the study device post-market clinical follow up surveillance plan and prospective clinical evidence collection.


Description:

The proposed Post-Market Clinical Follow-up study is a Prospective, Multi-Center, Observational Study, aiming to further demonstrate the safety and effectiveness of the FemoSealTM VCS in achieving hemostasis of common femoral artery (CFA) access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 European sites. Follow-ups are scheduled at 30 days (±7 days) by hospital visit or telephone call. The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation & consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in Data Monitoring Plan. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements. The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation.


Recruitment information / eligibility

Status Completed
Enrollment 230
Est. completion date August 3, 2022
Est. primary completion date July 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is = 18 years old 2. Subject is willing and able to complete the follow-up requirements 3. Subject has the mental capacity (i.e. does not require the use of a Legally Authorized Representative) to sign the study Informed Consent Form (ICF) 4. Patient undergoing diagnostic or interventional endovascular procedure compatible with the use of FemoSeal™ VCS 5. Puncture site located at the CFA (i.e. between the inferior epigastric artery and the bifurcation of the superficial and profunda femoral arteries) 6. FemoSeal™ VCS deployed as per instruction for use by a trained operator on arteriotomy where sheaths or devices of =7F were used, following a femoral artery angiogram Exclusion Criteria: 1. Any contraindication to the endovascular treatment and/or FemoSeal™ VCS use as per IFU 2. Use of the FemoSeal™ VCS on puncture sites other than CFA 3. Repuncture of the CFA within 90 days at the same access site 4. Enrollment of a patient with the contralateral CFA puncture, when a prior target limb access site has been selected for the study and a FemoSealTM deployment has been performed. Additionally, patients will be examined intraoperatively and excluded from the study if any of the following were observed by the treating physician: 5. Lumen diameter of CFA < 5 mm 6. Stenosis and/or significant plaque present in the vicinity of the CFA puncture site 7. Arterial puncture is at, or distal to, the femoral artery bifurcation 8. Anomalous branches or vessel abnormalities present in the vicinity of the CFA puncture site 9. Use of > 7F primary introducer sheaths or devices 10. Multiple femoral punctures 11. Known or suspected posterior femoral wall puncture 12. Any condition that would make use of the closure device inappropriate (as per investigators' discretion)

Study Design


Locations

Country Name City State
Belgium AZ Sint Blasius Dendermonde
France Hôpital Paris St Joseph, Vascular and endovascular surgical center Paris
Germany Universitäts-Herzzentrum Freiburg Bad Krozingen, Department of Cardiology and Angiology Department Bad Krozingen Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
Terumo Europe N.V.

Countries where clinical trial is conducted

Belgium,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness endpoint: Successful puncture site haemostasis Cessation of arterial bleeding (excluding oozing) achieved in the CathLab in subjects not requiring any adjunctive intervention at the access site, including (but not limited to) sterile wound dressing and/or manual compression. within 6 hours post procedure
Primary Safety endpoint: Freedom from major complications Freedom from major complications of the access site limb within 6 hours post procedure
Secondary Freedom from any minor complications at the target limb access site. Minor complications are defined as:
Any puncture site-related haematoma (i.e. a palpable groin swelling measured at the longest diameter)
Minor (<5 cm) or
Major (=5 cm)
Pseudoaneurysms attributable to the study device
Arteriovenous fistulas
Minor access site infections (i.e. all infections not defined as major)
within 6 hours post procedure
Secondary Freedom from any major and minor complications at the target limb access site. within 6 hours to 30 days post-procedure
Secondary Time to hemostasis (TTH) Defined as time between the removal of the procedural sheath up to first observed arterial bleeding cessation (excluding oozing at access site) in subjects not requiring adjunctive intervention in the cathlab. up to 1 day
Secondary Time to ambulation (TTA) Defined as the time between the procedural sheath removal and the moment when the patient is able to ambulate, i.e. autonomously stand up from the bed and walk without recurrent bleeding. up to 30 days
Secondary Length of stay in hospital i. e. the time between the procedural sheath removal and the moment when the patient is discharged from the hospital up to 30 days
Secondary Quality of Life assessment Quality of Life assessed as per EuroQl five-dimensional (EQ-5D) questionnaire:
The first part of the questionnaire contain descriptive questions on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, each with 5 levels of responses.
The second part of the questionnaire contains a standard vertical 20-cm visual analog scale that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex.
at baseline, discharge , and 30 days
Secondary FemoSeal™ VCS usability Accessed by questionnaire, including, but not limited to the following items (usefulness; ease of use; ease of learning; satisfaction and intention to use) completed by operators. up to 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05335525 - Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
Active, not recruiting NCT01903044 - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating Phase 1/Phase 2
Completed NCT02271529 - Zilver PTX Delivery System N/A
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Recruiting NCT02054871 - RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty N/A
Completed NCT00822172 - Evaluation of Cilostazol in Combination With L-Carnitine Phase 4
Completed NCT00574782 - Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE) N/A
Completed NCT00029991 - Extract of Ginkgo Biloba (EGB 761) and Vascular Function Phase 1/Phase 2
Completed NCT01355406 - Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System N/A
Recruiting NCT05804097 - Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? Phase 4
Recruiting NCT03638115 - The VaSecure BTK Study N/A
Active, not recruiting NCT03241459 - Safety and Efficacy of the SurVeil™ Drug-Coated Balloon N/A
Active, not recruiting NCT01661231 - Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe N/A
Completed NCT01722877 - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions N/A
Completed NCT01444378 - Absolute Pro® MOMENTUM™ N/A
Completed NCT00753337 - The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study N/A
Completed NCT00538226 - Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg Phase 1
Completed NCT00593385 - Atrium iCAST Iliac Stent Pivotal Study N/A
Recruiting NCT00385385 - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease Phase 2
Completed NCT00392509 - ALD-301 for Critical Limb Ischemia, Randomized Trial Phase 1/Phase 2